Lakefront Biotherapeutics has strung together three straight earnings beats and carries a wide stated margin of safety, but revenue is collapsing and margins are deeply compressed, the stock remains in a confirmed downtrend despite a recovering setup, and it has already reached its price target amid a leadership-change flag with a sharply negative stated risk/reward.
Thesis pillars
- Revenue Collapse Margin Compression↓Deteriorating
- Wide Margin Of Safety Valuation→Stable
- Recent Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
Lakefront Biotherapeutics (LKFT) Stock Analysis
Falling Knife setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $27.84 — A.R:R is negative (-4.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus... Read more
Sell if holding. Analyst target reached at $27.84 — A.R:R is negative (-4.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Score 5.4/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 16d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-07-25Recent Developments — Lakefront Biotherapeutics
Latest news
- NEWS Lakefront Biotherapeutics Receives Transparency Notification As Madison Avenue Partners Crossed Above 5% Of Voting Right — benzinga Jun 29, 2026 neutral
Generated 2026-07-25T14:18:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $27.84 — A.R:R is negative (-4.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Prior stop was $26.95. Score 5.4/10, moderate confidence.
Take-profit target: $30.29 (-23.1% upside). Prior stop was $26.95. Stop-loss: $26.95.
Analyst target reached - limited upside remaining; Negative momentum; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend).
Lakefront Biotherapeutics trades at a P/E of 3.3 (forward -14.3). TrendMatrix value score: 5.6/10. Verdict: Sell.
18 analysts cover LKFT with a consensus score of 2.6/5. Average price target: $25.
What does Lakefront Biotherapeutics do?Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily...
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.